GSK 3036656

Drug Profile

GSK 3036656

Alternative Names: GSK 3036656

Latest Information Update: 18 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 02 Apr 2017 Phase-I clinical trials in Tuberculosis (In volunteers) in United Kingdom (PO) (NCT03075410)
  • 16 Mar 2017 GlaxoSmithKline plans a phase I trial for Tuberculosis (In volunteers) in United Kingdom (NCT03075410)
  • 01 Mar 2017 Preclinical trials in Tuberculosis in United Kingdom (PO) before March 2017 (NCT03075410)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top